查看文章

Since March 2020, hospitals around the world have worked tirelessly to contain the spread of the novel severe acute respiratory syndrome coronavirus 2 and acutely treat the millions of patients who fell prey to COVID‐19. Although the acute threat has begun to subside, clinicians now face the dilemma of how best to treat those with long‐term residual respiratory symptoms. Although pulmonary fibrosis accounts for these findings in 20–30% of survivors of severe COVID‐19, the clinical conundrum lies in those patients with residual debilitating shortness of breath, yet no imaging or testing abnormalities. This begs the question whether the pulmonary symptoms these patients experience are related primarily to the lung or are instead the result of other etiologies, such as occult thromboembolic disease, cardiac dysfunction, muscular weakness, or viral‐induced dysautonomic regulation of …